Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vudalimab + olaparib
- Development stage
- Unknown
- Lead developer
- Xencor
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Vudalimab + olaparib is a combination of two anticancer agents under clinical investigation for the treatment of metastatic castration-resistant prostate cancer (mCRPC), particularly in patients with homologous recombination deficiency or CDK12 biallelic loss. Vudalimab is a humanized bispecific monoclonal antibody that blocks both PD-1 and CTLA-4 checkpoint pathways, designed to promote T-cell mediated antitumor immunity by preferentially binding PD-1/CTLA-4 dual-positive cells. Olaparib is a small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP), a key enzyme involved in DNA damage repair, with activity against tumors with homologous recombination repair defects. The combination aims to enhance immune-mediated tumor destruction and genomic instability in tumors, leveraging both checkpoint inhibition and synthetic lethality.
- Other names
- vudalimab + olaparib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PARP3 (Poly(adp-ribose) polymerase 3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on vudalimab + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vudalimab + olaparib.